DIFFERENCE OF SGOT AND SGPT LEVEL IN STADIUM IIB-IIIB SQUAMOUS CELL CERVICAL CANCER PATIENTS BEFORE AND AFTER CHEMOTHERAPY AT SANGLAH HOSPITAL DENPASAR
Abstract
Objective:Cervical cancer became Indonesia’s highest prevalent gynecological cancer in 2013 and the highest
prevalent gynecological cancer at Sanglah Hospital.Paclitaxel Carboplatin is one of the regimens used for
cervical cancer treatment at Sanglah Hospital, Denpasar. Aside of providing therapeutic effect, this regimen also
causes hepatotoxicity. This research was trying to determine the toxic effect of Paclitaxel Carboplatin towards
liver function based on the difference of SGOT and SGPT levels before chemotherapy cycle I and after
chemotherapy cycle VI. Method:This wasa prospective observational research with a study case method
conducted from January 2017 until June 2017 at Obstetric Polyclinic of Sanglah Hospital, Denpasar.Samples’
SGOT and SGPT level before and after chemotherapy I and VI were recorded and were then analysed with
Shapiro-Wilk normality test. If the data were distributed normally, they would undergo tpaired test and
Wilcoxon test at 95% confidence level if they were not distributed normally. Results: Tenpatients fulfilled the
research criteria. There was a meaningless increase for SGOT level (p=0.575) along with a meaningless increase
for SGPT level (p=0.074) before and after Paclitaxel Carboplatin chemotherapy cycle I and VI
respectively.Conclusion: Research of toxic effect from Paclitaxel Carboplatin chemotherapy in 10 squamous
cell cervical cancer patients showed a meaningless difference of both SGOT and SGPT level with the value of
p>0.05 in stadium IIB-IIIB squamous cell cervical cancer patients before and after Paclitaxel Carboplatin
chemotherapy cycle I and VI respectively.
Downloads
References
Estimated Incidence, Mortality and
Prevalence Worldwide in 2012 [Online].
Lyon, France: International Agency for
Research on Cancer (IARC). Available:
http://globocan.iarc.
[2] Kemenkes RI. (2015a). Pusat Data
danInformasiKementrianKesehatan RI.
Jakarta: KementerianKesehatanRepublik
Indonesia
[3] Herfindal, E. T., and D. R. Gourley. (2000).
Textbook of Therapeutics Drugs and Disease
Management. USA: Lippincott Williams &
Wilkins.
[4] Wiebe, E. L. Denny, and G. Thomas. (2012).
Cancer of the Cervix Uteri.International
Journal of Gynecology and Obstetrics.
119S2. pp. S100-S109.
[5] KomiteMedik RSUP Sanglah. (2011).
ProtokolKemoterapiOnkologiGinekologi.
Denpasar: RumahSakitUmumPusatSanglah.
[6] Chan, J. K., C. Tian, G. F. Fleming, B. J.
Monk, T. J. Herzog, D. S. Kapp, and J. Bell.
(2010). The Potential Benefit of 6 Vs 3
Cycles of Chemotherapy In Subsets of
Women with Early-Stage High-Risk
Epithelial Ovarian Cancer: An Exploratory
Analysis of a Gynecologic Oncology Group
Study. Gynecologic Oncology. 116. Pp. 301–
306.
[7] Smith, I. E., M. E.R. O’Brien, D. C. Talbot,
M. C. Nicolson, J.L. Mansi, T. F. Hickish, et
al. (2001).Duration of Chemotherapy in
Advanced Non–Small-Cell Lung Cancer: A
Randomized Trial of Three Versus
SixCourses of Mitomycin, Vinblastine, and
Cisplatin. Journal of Clinical
Oncology.19(5).pp. 1336-1343.
[8] Sweetman, S. C. (2009).Martindale: The
Complete Drug Reference, Thirty-sixth
Edition. London: Pharmaceutical Press.
[9] Sumardjo, D. (2006). Pengantar Kimia
BukuPanduanKuliahMahasiswaKedokteran
dan Program Strata I FakultasBioeksata.
Jakarta: PenerbitBukuKedokteran EGC.
[10] Bastiyansyah, E.
(2008).PanduanLengkapMembacaTesKeseh
atan. Jakarta: Penebar Plus.
[11] Kemenkes RI. (2015b).
PanduanPelayananKlinisKankerServiks.
